Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

Hang Lee, Ph.D.

Co-Author

This page shows the publications co-authored by Hang Lee and Joel Finkelstein.
Connection Strength

2.298
  1. Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men. J Clin Endocrinol Metab. 2020 08 01; 105(8).
    View in: PubMed
    Score: 0.222
  2. Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. J Clin Endocrinol Metab. 2020 04 01; 105(4).
    View in: PubMed
    Score: 0.217
  3. Effect of Testosterone on Natriuretic Peptide Levels. J Am Coll Cardiol. 2019 03 26; 73(11):1288-1296.
    View in: PubMed
    Score: 0.202
  4. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016 Mar 01; 126(3):1114-25.
    View in: PubMed
    Score: 0.163
  5. Differences in skeletal microarchitecture and strength in African-American and white women. J Bone Miner Res. 2013 Oct; 28(10):2177-85.
    View in: PubMed
    Score: 0.138
  6. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 Sep 12; 369(11):1011-22.
    View in: PubMed
    Score: 0.138
  7. Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women. Bone. 2011 Apr 01; 48(4):713-9.
    View in: PubMed
    Score: 0.113
  8. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010 Apr; 95(4):1838-45.
    View in: PubMed
    Score: 0.107
  9. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009 Aug; 94(8):2915-21.
    View in: PubMed
    Score: 0.102
  10. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009 Jul; 94(7):2495-501.
    View in: PubMed
    Score: 0.102
  11. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15; 112(10):2188-94.
    View in: PubMed
    Score: 0.095
  12. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug; 21(8):1187-96.
    View in: PubMed
    Score: 0.084
  13. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug; 91(8):2882-7.
    View in: PubMed
    Score: 0.083
  14. Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2006 Mar; 91(3):1069-75.
    View in: PubMed
    Score: 0.080
  15. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005 Oct 15; 104(8):1633-7.
    View in: PubMed
    Score: 0.080
  16. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Aug; 89(8):3841-6.
    View in: PubMed
    Score: 0.073
  17. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 01; 22(13):2546-53.
    View in: PubMed
    Score: 0.073
  18. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003 Sep 25; 349(13):1216-26.
    View in: PubMed
    Score: 0.069
  19. Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women. J Clin Endocrinol Metab. 2002 Dec; 87(12):5449-54.
    View in: PubMed
    Score: 0.065
  20. FSH suppression does not affect bone turnover in eugonadal men. J Clin Endocrinol Metab. 2014 Jul; 99(7):2510-5.
    View in: PubMed
    Score: 0.036
  21. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab. 2014 Apr; 99(4):1322-9.
    View in: PubMed
    Score: 0.035
  22. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42.
    View in: PubMed
    Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.